The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index

1. Introduction

Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western countries and is characterized by a marked clinical, molecular, and prognostic heterogeneity [1]. While some patients without treatment have a life expectancy equal to that of the healthy population, others require treatment from the beginning of the disease and may even die within a short period of time [2–4]. For this reason, more than 35 years ago, the Rai [5] and Binet [6] classifications appeared. Although these classifications are widely used, they have shown certain limitations in the ability to predict which patients will have a more aggressive progression and which ones will respond worse to treatment [1].

In recent years, many studies have been carried out to identify characteristics and biomarkers related to the tumor...
process and to the patient. From these results, it has been possible to establish new PIs that solve most of the limitations of classical staging systems. The advances in the identification of cytogenetic alterations analyzed by fluorescence in situ hybridization (FISH) are worth mentioning, which distinguish groups with favorable prognosis (13q deletion [13q-]) and unfavorable prognosis (11q deletion [11q-] or 17p deletion [17p-]) [7]. Likewise, the study of somatic mutations in the variable region of the immunoglobulin heavy chain gene (IGHV) has shown that patients with mutated pattern have favorable outcome [8–10].

In 2007, the MD Anderson Cancer Center (MDACC) [11] designed a nomogram out of a retrospective study of 1,674 patients diagnosed with CLL. Prognostic factors included were sex, age, absolute lymphocyte count, β2-microglobulin, Rai stage, and the number of nodal regions affected. Although this prognostic index (PI) has been validated extensively by other groups [12–18] and is very useful because of its simple application, its main limitation is that the parameters included are closely related to the tumor burden and not to genetic factors [19].

Recently, the chronic lymphocytic leukemia international prognostic index (CLL-IPI) [20], which combines genetic, biochemical, and clinical parameters in a prognostic model, has been published, based on the results of a meta-analysis and subsequently validated in other publications [13, 21, 22]. The CLL-IPI includes five variables (mutation or chromosomal status of the TP53/17p- gene, serum β2-microglobulin, mutation status of IGHV, Rai/Binet clinical stage, and age) and assigns a score according to their greater or lower prognostic impact.

With the aim to facilitate the use of the CLL-IPI in routine clinical practice, a simplified version of this PI, performed by Hospital Clinic Barcelona, University of Brno Hospital, Azienda Ospedaliera Pugliese-Ciaccio, and Azienda Ospedaliera di Cosenza groups, which only includes IGHV mutation status and FISH cytogenetics, has been proposed recently. It has shown a similar discriminatory value to the CLL-IPI and has been applied independently of age, separating patients with different risks among the same clinical stage groups [23].

The objective of this work is the evaluation of the validity and reproducibility of the CLL-IPI, the Barcelona-Brno biomarkers only prognostic model, and its comparison with the MDACC in a cohort of Spanish patients.

2. Materials and Methods

2.1. Patients. A total of 696 unselected CLL patients newly diagnosed and previously untreated from different institutions of the central region of Spain were included in this study. The data collection period began in 2004 and ended in 2014. This study was approved by the local ethics committee, and the ethical norms of the Declaration of Helsinki were followed.

The database contains information about demographic (age and sex), clinical (nodal regions affected, hepatomegaly, and splenomegaly), analytical (blood counts, LDH, and β2-microglobulin), and genetic abnormalities determined by FISH (11q-, trisomy 12, 13q-, and 17p-), immunophenotypic (CD38 and ZAP70 expression) and molecular (somatic mutations of the IGHV gene) variables, and Rai and Binet clinical stages. A review of the patients’ medical records was carried out, and 107 cases were excluded of the analysis due to incomplete data. Finally, 483 patients were included to assess the MDACC PI and 258 for the CLL-IPI and the Barcelona-Brno biomarkers only prognostic model, as the remaining cases did not have information about the mutation status of the IGHV gene.

2.2. MDACC Prognostic Index. The classification in the three groups of risk proposed by the MDACC, low risk (1–3 points), intermediate risk (4–7 points), and high risk (≥8 points), was determined from the sum of the points assigned to six prognostic factors [11]. The index was calculated after assigning 1 point for age < 50 years, male sex, level of β2-microglobulin 1–2x upper limit of normality, absolute lymphocyte count of 20–50 × 10⁹/L, Rai stage III or IV, and ≥3 nodal regions affected; 2 points for age 50–65 years, β2-microglobulin >2x upper limits of normality, and absolute lymphocyte count >50 × 10⁹/L; and 3 points for age > 65 years.

2.3. CLL-IPI. In order to stratify patients according to the CLL-IPI, 4 points were assigned for 17p- mutation, 2 points for unmutated IGHV status and serum β2-microglobulin >3.5 mg/L, and 1 point for age > 65 years and advanced clinical stage (Rai I–IV or Binet B–C). As TP53 mutational status was not available in the database, only 17p- was used to assess TP53 status. The sum of these scores identified patients in 4 subgroups: low risk (0-1 points), intermediate risk (2-3), high risk (4–6), and very high risk (7–10) [20].

2.4. Barcelona-Brno Biomarkers Only (IGHV Mutational Status and FISH Cytogenetics Prognostic Model). The simplified version of the CLL-IPI defined high-risk patients as those with adverse FISH cytogenetics (11q- and/or 17p-) and an unmutated IGHV status, low-risk patients as those without adverse cytogenetics and mutated IGHV status, and intermediate-risk patients as those not included in the previous groups [23].

2.5. Statistical Analysis. Statistical analysis was performed using the SPSS software package version 21.0. Overall survival (OS) was calculated from the time of diagnosis to death or last follow-up and time to first therapy (TTFT) from the date of diagnosis to first treatment or last follow-up. Both variables were estimated by the Kaplan-Meier method and assessed by the log-rank test. Cox regression was used for univariate and multivariate analyses of the impact of variables on OS. These data were expressed as the hazard ratio (HR) with a 95% confidence interval (95% CI). On the other hand, the area under the ROC (receiver’s operating characteristic) curve was used to find the discrimination of models. In the same way, a 95% CI was established, in which 0.5 implies that the model offers random results and 1 implies that the model is a perfect predictor of survival. The value of p < 0.05 was considered significant for all analyses.
Table 1: Clinical characteristics of the patients included for the validation of the MDACC prognostic index.

| Patients (%) | Median (Q1, Q3) |
|--------------|----------------|
| **Age (years)** | |
| <50 | 37 (27) |
| 50–65 | 172 (35.6) |
| >65 | 274 (56.7) |
| **Sex** | |
| Male | 310 (64.2) |
| Female | 173 (35.8) |
| **Lymphocyte count \((×10^9/L)\)** | 13.0 (8.6–22.6) |
| <20 | 346 (71.6) |
| 20–50 | 93 (19.3) |
| >50 | 44 (9.1) |
| **Hemoglobin (g/dL)** | 14.3 (13.1–15.3) |
| ≤10 | 22 (4.6) |
| >10 | 461 (95.4) |
| **Platelet count \((×10^9/L)\)** | 2.15 (1.6–3.0) |
| ≤100 | 239 (49.2) |
| >100 | 456 (94.4) |
| **β2-microglobulin (mg/L)** | |
| Normal | 239 (49.2) |
| 1-2xULN | 184 (37.9) |
| >2xULN | 63 (12.9) |
| **LDH (UI/L) \((n = 401)\)** | 323 (271–393) |
| Enlarged node regions | |
| ≤2 | 395 (81.9) |
| >2 | 88 (18.2) |
| Splenomegaly | |
| Yes | 80 (16.6) |
| Not | 403 (83.4) |
| Hepatomegaly | |
| Yes | 35 (7.2) |
| Not | 448 (92.8) |
| **Rai staging system** | |
| 0-2 | 453 (93.8) |
| 3-4 | 30 (6.2) |
| **FISH** | |
| Del1q | 34 (7.0) |
| Trisomy 12 | 57 (11.8) |
| Del3q | 192 (39.8) |
| Del7p | 21 (4.3) |
| Normal | 179 (37.1) |
| **ZAP70 \((N = 183)\)** | 103 (39.9) |
| Positive | 29 (15.8) |
| Negative | 154 (84.2) |
| **CD38 \((N = 338)\)** | 45 (23.4) |
| Positive | 79 (23.4) |
| Negative | 259 (76.6) |

Q1: quartile 1; Q3: quartile 3; ULN: upper limit normal; MDACC: MD Anderson Cancer Center.

3. Results

3.1. Patients Characteristics. A total of 483 patients with CLL were included in the analysis of the MDACC prognostic index. The principal characteristics of these patients are shown in Table 1. Of note, most of the patients presented with early clinical Rai or Binet stages. The median age at diagnosis was 67 years (range: 25–90) and most patients were older than 50 (92.3%). After a median follow-up period of 46 months (range: 1–277), 92 individuals had died and 186 had required treatment. The median time to treatment was 32 months (range: 0–264).

The analysis for the validation of CLL-IPI and the Barcelona-Brno biomarkers only prognostic model included 258 patients. Table 2 illustrates the main characteristics of this subgroup of patients. Analogously to the previous cohort, the majority of the patients presented with early Rai or Binet...
stages. In this cohort, the median follow-up period was 68 months (range: 3–277), during which 47 patients died and 113 were treated. The median period to the treatment was 31 months (range: 0–264).

3.2. Application of the MDACC Prognostic Index. The distribution of patients in the three prognostic groups proposed by the index was 160 (33.1%) patients at low risk, 302 (62.5%) at intermediate risk, and 21 (4.4%) at high risk. This division of the patients proved to have a statistically significant association with OS (Figure 1(a)). The probability of 5-year survival and 10-year survival showed significant differences between risk groups (Table 3).

This index also showed a significant association with TTFT (Figure 1(b)). The probability of treatment at 5 years and 10 years is shown in Table 3.

3.3. Application of the CLL-IPI Prognostic Index. Patients were divided into the four prognostic groups proposed by the CLL-IPI as follows: 126 (48.8%) at low risk, 79 (30.6%) at intermediate risk, 46 (17.8%) at high risk, and 7 (2.7%) at very high risk. The model proved to be statistically significant in the prediction of OS (Figure 2(a)). The probability of 5-year survival and 10-year survival showed significant differences between risk groups (Table 3).

The CLL-IPI also showed a statistically significant association with TTFT (Figure 2(b)). The probability of treatment at 5 years and 10 years is shown in Table 3.

Detailed univariate and multivariate Cox regression analyses of the variables included in the CLL PI are shown in Tables S1 and S2.

3.4. Application of the Barcelona-Brno Biomarkers Only Prognostic Model. The Barcelona-Brno biomarkers only prognostic model also distinguished 3 groups of patients with different OS: 145 (56.2%) patients at low risk, 91 (35.3%) at intermediate risk, and 22 (8.9%) at high risk (Figure 3(a)). The probability of 5-year survival and 10-year survival also showed significant differences between risk groups (Table 3). In addition, this index showed a statistically significant association with TTFT (Figure 3(b)). The probability of treatment at 5 years and 10 years is described in Table 3.

3.5. Comparison of the Three Indexes. The ROC curve to verify the discriminatory capacity of the index proposed by the MDACC showed a c-statistic value of 0.652 for OS and 0.614 for TTFT (p < 0.0001 in both). The c-statistic ROC curve of CLL-IPI was 0.676 for OS and 0.757 for TTFT (p < 0.0001 in both). The c-statistic of the Barcelona-Brno
Figure 2: Survival analysis for patients stratified according to the CLL-IPI score. (a) Overall survival analysis. (b) Time to first therapy analysis.

Figure 3: Survival analysis for patients stratified according to the Barcelona-Brno biomarkers only prognostic model. (a) Overall survival analysis. (b) Time to first therapy analysis.
Table 3: Overall survival and time to first therapy data of the MDACC PI, the CLL-IPI, and the Barcelona-Brno biomarkers only prognostic model risk groups.

### MDACC PI

| Group      | N    | Median OS (95% CI) | 5-year OS | 10-year OS | HR (95% CI) | p     |
|------------|------|--------------------|-----------|------------|-------------|-------|
| Low risk   | 160  | 238.5 (146–330.0)  | 98.4      | 91.6       | 1 (ref)     |       |
| Intermediate risk | 302  | 142 (132–151.9)    | 79.6      | 61.6       | 4.8 (2.6–9.1) | <0.0001|
| High risk  | 21   | 63.5 (52.6–74.4)   | 51.1      | 15.3       | 5.3 (0–9.2)  | <0.0001|

| Group      | N    | Median TTFT (95% CI) | 5-year TTFT | 10-year TTFT | HR (95% CI) | p     |
|------------|------|----------------------|-------------|--------------|-------------|-------|
| Low risk   | 160  | 133.0 (110.8–155.3)  | 20.3        | 47.5         | 1 (ref)     |       |
| Intermediate risk | 302  | 81 (46.6–115.4)     | 44.9        | 55.7         | 2.2 (1.5–4.8) | <0.0001|
| High risk  | 21   | 2.3 (0.3–4.4)       | 93.7        | 93.7         | 4.4 (3.2–6)  | <0.0001|

### CLL-IPI

| Group      | N    | Median OS (95% CI) | 5-year OS | 10-year OS | HR (95% CI) | p     |
|------------|------|--------------------|-----------|------------|-------------|-------|
| Low risk   | 126  | 238.5 (147–330)    | 93.6      | 89.6       | 1 (ref)     |       |
| Intermediate risk | 79   | 144.8 (127.8–161.8) | 87.6      | 74.5%      | 3.2 (1.5–6.7) | <0.0001|
| High risk  | 49   | 73.7 (56.6–90.7)   | 67.8      | 26.8       | 2.2 (2.1–4.8) | <0.0001|
| Very high risk | 7    | 31.8 (21.2–42.4)   | 28.6      | NE*         | 4.4 (3.2–6)  | <0.0001|

| Group      | N    | Median TTFT (95% CI) | 5-year TTFT | 10-year TTFT | HR (95% CI) | p     |
|------------|------|----------------------|-------------|--------------|-------------|-------|
| Low risk   | 126  | Not reached          | 15.8        | 29.4         | 1 (ref)     |       |
| Intermediate risk | 79   | 52.9 (34.5–71.3)    | 55          | 79.1         | 4.4 (2.7–7.2) | <0.0001|
| High risk  | 46   | 7.6 (5–10)           | 93.4        | 93.4         | 3.7 (2.8–4.9) | <0.0001|
| Very high risk | 7    | 9.6 (0–21)          | NE**        | NE**         | 2.2 (1.6–3.2) | <0.0001|

### Barcelona-Brno PI

| Group      | N    | Median OS (95% CI) | 5-year OS | 10-year OS | HR (95% CI) | p     |
|------------|------|--------------------|-----------|------------|-------------|-------|
| Low risk   | 145  | 238.5 (146.8–330)  | 90.7      | 86         | 1 (ref)     |       |
| Intermediate risk | 91   | 131.9 (95–167.9)   | 81.4      | 61.1       | 4.34 (2.85–6.63) | <0.0001|
| High risk  | 22   | Not reached        | 66.2      | 53         | 9.37 (5.12–17.14) | <0.0001|

| Group      | N    | Median TTFT (95% CI) | 5-year TTFT | 10-year TTFT | HR (95% CI) | p     |
|------------|------|----------------------|-------------|--------------|-------------|-------|
| Low risk   | 142  | 182.2 (83.9–280.4)  | 19.9        | 35.8         | 1 (ref)     |       |
| Intermediate risk | 91   | 131.5 (14.4–48.5)   | 64.7        | 82.4         | 2.95 (1.57–5.52) | <0.0001|
| High risk  | 21   | 9.8 (2.4–17.2)      | 91.6        | 91.6         | 4.24 (1.67–10.97) | <0.0001|

NE: not evaluable. NE*: last control in month 94. NE**: last control in month 45. MDACC: MD Anderson Cancer Center. CLL-IPI: chronic lymphocytic leukemia international prognostic index.

Biomarkers only prognostic model for OS was 0.600 (p = 0.03) and for TTFT was 0.722 (p < 0.001).

The ROC curves are shown in Figures S1, S2, and S3.

### 4. Discussion

CLL is a disease with an extremely variable clinical outcome. Nowadays, despite the discovery of new drugs focused on new targets, CLL is not considered curable. Several PIs have been developed in previous years to refine the prognosis of CLL patients. The objective of these new scores is to apply them in daily clinical practice, to improve risk stratification and, as possible, to predict response to therapy. Currently, **TP53 mutations/17p deletions and the mutational status of IGHV gene constitute the main predictive factors in CLL patients [23–25].**

Therefore, in this study, performed with a representative sample of patients with CLL, the application of different previously published prognostic systems is analyzed. The characteristics of the patients included in the study are similar to previous publications [12, 13, 20, 26–28] and representative of the patients diagnosed in usual clinical practice. This made it possible to overcome the main limitation of the MDACC study by Wierda et al. [11], in which the median age at diagnosis was not clearly representative of patients with CLL (58 years old).

Our study has confirmed the ability of the three PIs to stratify patients according to its clinical outcome. The 5-year OS and 10-year OS obtained in the three cohorts of the study were similar to those published in the MDACC PI, CLL-IPI, and Barcelona-Brno biomarkers only prognostic model [11, 17, 18, 20, 23] except in the very high risk CLL-IPI group [20]. This fact may be due to the low number of patients classified in this subgroup and could also be explained by the absence of data about the mutation **TP53** in this study. This mutation occurs around 10–15% in the absence of 17p deletion [29], so a small percentage of patients may not have been classified in the very high risk group in our study.
index proposed by the MDACC should not be relegated, since, besides being easily applicable, it has been validated on several occasions [12–18].

**Conflicts of Interest**

The authors declare that there are no conflicts of interest regarding the publication of this article.

**Authors’ Contributions**

Carolina Muñoz-Novas, María Poza-Santaella, Isabel González-Gascón y Marín, and José-Ángel Hernández contributed equally to this paper.

**Acknowledgments**

The authors thank all the physicians from the Spanish institutions who contributed clinical data, Grupo Español de Leucemia Linfocítica Crónica, and Grupo Cooperativo Español de Citogenética Hematológica.

**Supplementary Materials**

Table S1: univariate and multivariate Cox regression analyses of the variables included in the MDACC score. Table S2: univariate and multivariate Cox regression analyses of the variables included in the CLL-IPI score. Figure S1: ROC curve for MDACC PI. (A) Overall survival. (B) Time to first therapy. Figure S2: ROC curve for CLL-IPI. (A) Overall survival. (B) Time to first therapy. Figure S3: ROC curve for Barcelona-Brno biomarkers only prognostic model. (A) Overall survival. (B) Time to first therapy. (Supplementary Materials)

**References**

[1] P. Baliakas, M. Mattsson, K. Stamatopoulos, and R. Rosenquist, “Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?” *Journal of Internal Medicine*, vol. 279, no. 4, pp. 347–357, 2016.

[2] T. J. Kipps, F. K. Stevenson, C. J. Wu et al., “Chronic lymphocytic leukaemia,” *Nature Reviews Disease Primers*, vol. 3, article 17008, 2017.

[3] G. Dighiero, “CLL biology and prognosis,” *Hematology/The Education Program of the American Society of Hematology. American Society of Hematology. Education Program*, vol. 2005, no. 1, pp. 278–284, 2005.

[4] J. Á. Hernández, M. González, and J. M. Hernández, “Chronic lymphocytic leukemia,” *Medicina Clínica*, vol. 135, no. 4, pp. 172–178, 2010.

[5] K. R. Rai, A. Sawitsky, E. P. Cronkite, A. D. Chanana, R. N. Levy, and B. S. Pasternack, “Clinical staging of chronic lymphocytic leukemia,” *Blood*, vol. 46, no. 2, pp. 219–234, 1975.

[6] J. L. Binet, A. Auquier, G. Dighiero et al., “A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis,” *Cancer*, vol. 48, no. 1, pp. 198–206, 1981.
[7] D. E. Gladstone, A. Blackford, E. Cho et al., “The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia,” Clinical Lymphoma, Myeloma & Leukemia, vol. 12, no. 2, pp. 132–137, 2012.

[8] T. J. Hamblin, Z. Davis, A. Gardiner, D. G. Oscier, and F. K. Stevenson, “Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia,” Blood, vol. 94, no. 6, pp. 1848–1854, 1999.

[9] I. González-Gascón Y Marín, J. A. Hernández, A. Martin et al., “Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia,” BioMed Research International, vol. 2014, Article ID 257517, pp. 1–8, 2014.

[10] R. N. Damle, T. Wasil, F. Fais et al., “Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia,” Blood, vol. 94, no. 6, pp. 1840–1847, 1999.

[11] W. G. Wierda, S. O’Brien, X. Wang et al., “Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia,” Blood, vol. 109, no. 11, pp. 4679–4685, 2007.

[12] M. Gentile, F. R. Mauro, D. Rossi et al., “Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukemia patients: analysis of 1502 cases,” British Journal of Haematology, vol. 167, no. 2, pp. 224–232, 2014.

[13] M. Gentile, T. D. Shanafelt, D. Rossi et al., “Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients,” Blood, vol. 128, no. 16, pp. 2093–2095, 2016.

[14] S. Molica, D. Giannarelli, M. Gentile et al., “External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia,” Cancer, vol. 119, no. 6, pp. 1177–1185, 2013.

[15] S. Molica, D. Giannarelli, R. Mirabelli et al., “Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: Results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model,” European Journal of Haematology, vol. 96, no. 1, pp. 72–77, 2016.

[16] A. P. González Rodríguez, E. González García, C. Fernández Álvarez, A. J. González Huerta, and S. González Rodríguez, “B-Chronic lymphocytic leukemia: Epidemiological study and comparison of MDACC and GIMENA prognostic indexes,” Medicina Clinica, vol. 133, no. 5, pp. 161–166, 2009.

[17] T. D. Shanafelt, G. Jenkins, T. G. Call et al., “Validation of a new prognostic index for patients with chronic lymphocytic leukemia,” Cancer, vol. 115, no. 2, pp. 362–373, 2009.

[18] P. Bulian, M. Tarnani, D. Rossi et al., “Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia,” Hematological Oncology, vol. 29, no. 2, pp. 91–99, 2011.

[19] N. Chiorazzi, K. R. Rai, and M. Ferrarini, “Chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 352, no. 8, pp. 804–850, 2005.

[20] International CLL-IPI working group, “An international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI): a meta-analysis of individual patient data,” The Lancet Oncology, vol. 17, no. 6, pp. 779–790, 2016.

[21] C. Da Cunha-Bang, I. Christiansen, and C. U. Niemann, “The CLL-IPI applied in a population-based cohort,” Blood, vol. 128, no. 17, pp. 2181–2183, 2016.

[22] S. Molica, T. D. Shanafelt, D. Giannarelli et al., “The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients,” American Journal of Hematology, vol. 91, no. 11, pp. 1090–1095, 2016.

[23] J. Delgado, M. Doubek, T. Baumann et al., “Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI,” American Journal of Hematology, vol. 92, no. 4, pp. 375–380, 2017.

[24] L. C. Gomes, A. L. M. Ferrão, F. C. G. Evangelista et al., “Advances in chronic lymphocytic leukemia pharmacotherapy,” Biomedicine & Pharmacotherapy, vol. 97, pp. 349–358, 2017.

[25] P. Robak and T. Robak, “Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia,” Expert Opinion on Investigational Drugs, vol. 26, no. 11, pp. 1249–1265, 2017.

[26] S. Molica, F. R. Mauro, V. Callea et al., “A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia,” Leukemia & Lymphoma, vol. 46, no. 4, pp. 553–560, 2005.

[27] S. Jeromin, S. Weissmann, C. Haferlach et al., “SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients,” Leukemia, vol. 28, no. 1, pp. 108–117, 2014.

[28] A. Visentin, M. Facco, F. Frezzato et al., “Integrated CLL scoring system, a new and simple index to predict time to treatment and overall survival in patients with chronic lymphocytic leukemia,” Clinical Lymphoma, Myeloma & Leukemia, vol. 15, no. 10, pp. 612–620.e5, 2015.

[29] T. Zenz, A. Kröber, K. Scherer et al., “Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up,” Blood, vol. 112, no. 8, pp. 3322–3329, 2008.

[30] M. Gentile, T. D. Shanafelt, F. R. Mauro et al., “Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: analysis of 1299 newly diagnosed cases,” American Journal of Hematology, vol. 93, no. 2, pp. E35–E37, 2018.

[31] N. Lamanna and S. O’Brien, “Novel agents in chronic lymphocytic leukemia,” International Journal of Hematology, vol. 2016, no. 1, pp. 137–145, 2016.

[32] D. Rossi, S. Rasi, V. Spina et al., “Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia,” Blood, vol. 121, no. 8, pp. 1403–1412, 2013.

[33] S. A. Parikh, P. Strati, M. Tsang, C. P. West, and T. D. Shanafelt, “Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis,” Blood, vol. 127, no. 14, pp. 1752–1760, 2016.

[34] M. Hallek, B. D. Cheson, D. Catovsky et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines,” Blood, vol. 111, no. 12, pp. 5446–5456, 2008.